Effects of a step-therapy program for angiotensin receptor blockers antihypertensive medication utilization patterns and cost of drug therapy

Journal of Managed Care Pharmacy

Volumn 13, Issue 3, 2007, Pages 235-244

  Yokohama, Krista ^a   Yang, Winnie ^a   Preblick, Ronald ^b   Frech Tamas, Feride ^b  

^a Wellpoint Inc   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Angiotensin receptor blockers; Pharmacy costs; Prior authorization; Step therapy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CAPTOPRIL; CAPTOPRIL PLUS HYDROCHLOROTHIAZIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; FOSINOPRIL; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; LISINOPRIL;

ADD ON THERAPY; ADULT; ARTICLE; CONTROLLED STUDY; COST CONTROL; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; DRUG SUBSTITUTION; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; FINANCIAL MANAGEMENT; FOLLOW UP; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MANAGED CARE ORGANIZATION; PHARMACY; PHARMACY BENEFIT MANAGER; PRESCRIPTION; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 34248328405     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.3.235     Document Type: Article

References (16)

1. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. The Valsartan Heart Failure Trial investigators. N Engl J Med. 2001;345:1667-75.
2. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) study group. N Engl J Med. 1995;333:1670-76.
3. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-97.
4. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-52.
5. Olson BM. Approaches to pharmacy benefit management and the impact of consumer cost sharing. Clin Ther. 2003;25:250-72.
6. Novartis Pharmacy Benefit Report. 2006 Facts and Figures. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2006;18, 26.
7. Takeda Prescription Drug Benefit Cost and Plan Design Survey Report, 2005 ed. Scottsdale, AZ: Pharmacy Benefit Management Institute; 2005;13-15.
8. Curtiss F. Step-therapy edits for PPIs and COX-2 drugs - what we do and do not know [editorial]. J Manag Care Pharm. 2004;10(4):356. Available at: http://wwwamcp.org/data/jmcp/ Editorial-In%20This-355-358.pdf. Accessed February 22, 2007.
9. Etemad LR, Yu W. Outcomes of patients who were prescribed COX-2 inhibitor therapy but did not attempt prior authorization: a 6-month follow-up study [abstract]. J Manag Care Pharm. 2002;8(2):112. Available at: http://www.amcp.org/data/jmcp/2002_V8_I2.pdf. Accessed February 22, 2007.
10. Larson LW, Qualls BK, Ward J. COX-II inhibitor prior-authorization process: the untold story [abstract]. J Manag Care Pharm. 2001;7(5):366. Available at: http://www.amcp.org/data/jmcp/ Abstracts-355-373.pdf. Accessed February 22, 2007.
11. MacKinnon NJ, Kumar R. Prior authorization programs: a critical review of the literature. J Manag Care Pharm. 2001;7(4)297-302. Available at: http://www.amcp.org/data/jmcp/Review-297-302.pdf. Accessed February 22, 2007.
12. Stacy J, Shaw E, Arledge MD, et al. Pharmacoeconomic modeling of prior-authorization intervention for COX-2 specific inhibitors in a 3-tier copay plan. J Manag Care Pharm. 2003;9(4):327-34. Available at: http://www.amcp.org/data/jmcp/Research-327-334.pdf. Accessed February 22, 2007.
13. LaPensee KT. Analysis of a prescription drug prior authorization program in a Medicaid health maintenance organization. J Manag Care Pharm. 2003;9(1):36-44. Available at: http://www.amcp.org/data/jmcp/ Research-36-44.pdf. Accessed February 22, 2007.
14. Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Med Care. 1995;33:783-95.
15. Dunn JD, Cannon E, Mitchell MP, Curtiss FR. Utilization and drug cost outcomes of a step-therapy edit for generic antidepressants in an HMO in an integrated health system. J Manag Care Pharm. 2006;12(4):294-302. Available at: http://www.amcp.org/data/jmcp/ research_294-302.pdf. Accessed February 22, 2007.
16. Cox ER, Henderson R, Motheral BR. Health plan member experience with point-of-service prescription step therapy. J Manag Care Pharm. 2004;10(4):291-98. Available at http://www.amcp.org/data/jmcp/ 2004_V10_14.pdf. Accessed February 22, 2007.